The Gustave Roussy immune score as a novel biomarker for predicting survival in patients with isocitrate dehydrogenase wild-type glioblastoma treated with the Stupp protocol.

Background: Isocitrate dehydrogenase (IDH) wild-type (wt) glioblastoma is a biologically aggressive adult-type diffuse glioma with poor prognosis. Gustave Roussy Immune Score (GRIm-Score), reflecting systemic inflammation and nutritional status, has shown prognostic relevance in several cancers. Its prognostic value in IDH-wt glioblastoma remains undefined.